MD, FRCP(C)
Clinic Director and Staff Psychiatrist,
START Clinic for Mood and Anxiety Disorders
Faculty member, Northern Ontario School of Medicine,
Laurentian University and Lakehead University
Toronto, ON
Dr. Katzman is the Clinic Director and is a Staff Psychiatrist at the S.T.A.R.T. Clinic (Stress, Trauma, Anxiety, Rehabilitation and Treatment) for Mood and Anxiety Disorders. He is a faculty member at the Northern Ontario School of Medicine (Laurentian University and Lakehead University). He is also the past Acting Research Dean/Director and a full professor at Adler School of Professional Studies.
Dr. Katzman's research primarily involves examining the psychological manifestations associated with the prefrontal cortex and related associated tracts and organ systems in relation to the mood, anxiety, ADHD, obsessional and traumatic disorders. The focus of this research has been specifically directed at the study of Hypo-Prefrontality, Executive Dysfunction, Intolerance of Uncertainty and Reward Processing, including Hedonic Tone and Hedonic Capacity as the drivers of Motivation and Energy in relation to the development of a variety of comorbidities and treatment resistance. In the past he has used a variety of tools such as positron emission tomography, the respiratory physiological challenge, and doppler imaging, in association with a diverse anxiogenic challenges. He is also currently developing technologies to further help in the diagnosis and treatment of psychiatric disorders.
Dr. Katzman is the former Treasurer for The American Professional Society of ADHD and Related Disorders (APSARD) and was also a founding member of the Board of Directors as well as the founding Chair of the Scientific Advisory Board of the Anxiety Disorders Association of Canada/Association Canadienne des Troubles Anxieux (ADAC/ACTA), now known as Anxiety Canada. He is also the chair of a variety of scientific advisory boards, on the editorial board for a number of journals, and has published numerous papers in the areas of Anxiety, Mood, Pain and Attention Disorders and Complementary and Alternative Medicine.
His clinical work involves complex diagnosis and treatment using a variety of pharmacological tool, including cannabis, the hallucinogens and esketamine, as well as a variety of psychological treatments, including psychodynamic therapies, Cognitive Behavioural Therapy (CBT) and mindfulness based and experimental yoga-based therapies.
MD, FRCPC
Psychiatrist, Misericordia Hospital, Edmonton
Associate Clinical Professor, University of Alberta
Diplomate, American Board of Obesity Medicine
Edmonton, AB
Dr. Jennifer Swainson is a psychiatrist at the Misericordia Community Hospital in Edmonton, AB, and an Associate clinical professor in the Dept of Psychiatry at the University of Alberta. She has expertise in complex and difficult to treat mood disorders and their multiple common comorbidities. In particular, she has an interest in relationships between mood and metabolic disease and is she is certified by the American Board of Obesity Medicine.
Dr. Swainson is a co-author of the 2023 CANMAT Depression Treatment Guidelines and was lead author of the 2021 CANMAT Ketamine Depression Task force update. Dr. Swainson is a clinical researcher, primarily in the use of ketamine for depression and is an an active teacher and research supervisor for residents.
MD
Staff Psychiatrist, Clinician Scientist
Medical Head, Ambulatory Services, Lead Psychiatrist, Partial Hospital Program
Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), University of Toronto
Associate Professor, Department of Psychiatry, Faculty of Medicine, University of Toronto
Associate Member, Institute of Medical Science (IMS), University of Toronto
Toronto, ON
Dr. Ofer Agid is staff psychiatrist and a clinician scientist in the Schizophrenia Program at the Centre for Addiction and Mental Health in Toronto. Dr. Agid is the Medical Head, Ambulatory Services and the Lead Psychiatrist, Partial Hospital Program at the Schizophrenia Program. He is also Associate Professor in the Department of Psychiatry, Faculty of Medicine, University of Toronto and Associate Member, Institute of Medical Science (IMS), University of Toronto.
Areas of Research
Dr. Agid’s research focus is psychopharmacology in schizophrenia, specifically early response to antipsychotic medications, early predictors of response and treatment resistant schizophrenia. His work has uncovered a new “early onset of action” hypothesis of antipsychotics, which has impacted current practice guidelines for the treatment of schizophrenia.
As the medical leader in the First-Episode Schizophrenia program, Dr. Agid initiated an algorithm-based treatment approach for first-episode schizophrenia while collecting extensive clinical data regarding treatment response. This algorithm was implemented to optimize antipsychotic treatment during the earliest stages of the illness, a critical time period in terms of longer-term outcomes. This systematic and standardized approach has resulted in a large and comprehensive database; the published data to date have provided clear, empiric evidence that clinicians can use in approaching the pharmacological management of first-episode schizophrenia. It has also challenged current practice patterns and proven valuable in examining trajectories of response.
In addition, Dr. Agid is involved in investigating patterns of non-adherence and placebo response, treatment resistant schizophrenia, psychopharmacological mechanism of action of antipsychotics using brain imaging techniques and examining value systems and happiness in schizophrenia with an emphasis on the relationship to, and influence on, motivation and functional outcomes.
Dr. Agid is a recipient of numerous grants. He presented his research at major meetings and conferences and has published in major psychiatry journals.
MD, FRCPC
General Psychiatrist and Local Head of Department, Royal Columbian Hospital
Regional Division Head of Adult Psychiatry, Fraser Health
New Westminster, BC
Dr. Casey graduated from UBC medical school and residency. She is a general psychiatrist at Royal Columbian Hospital in New Westminster, BC. She practices inpatient, outpatient, and community psychiatry. She is the local department head at her hospital and the regional division head of adult psychiatry for Fraser Health. She is very involved in teaching and has taught hundreds of medical students and residents.
MD, CM, MSc, FRCPC
Director, PEPP-MUHC (program for the evaluation and prevention of psychosis)
Director, Schizophrenia program, MUHC
Associate Professor, Department of Psychiatry, McGill University
Dr. Margolese is an Associate Professor in the Department of Psychiatry of McGill University. He is currently the program director of the McGill Clinical Pharmacology and Toxicology residency program. He is director of the PEPP first episode psychosis and Schizophrenia programs at the McGill University Health Centre and director of the Clinical Psychopharmacology and Therapeutics Unit.
He has given numerous lectures and presentations both nationally and internationally and has published over 75 articles. He is vice-president of research and a founding member of the Canadian Consortium for Early Intervention in Psychosis.
In his clinical work, Dr. Margolese specializes in psychopharmacology consultations, first episode psychosis, and treatment resistant schizophrenia.
Professor
Dr. Paul Janssen Chair in Psychotic Disorders
Director of Research, Department of Psychiatry, Dalhousie University
Clinical Director, Early Psychosis Intervention Nova Scotia
Nova Scotia Health
Dr. Tibbo received his B.Sc. (Hons) from Mount Alison University in Sackville, NB, and his MD from Memorial University of Newfoundland. He completed his residency in psychiatry at the University of Alberta and following this joined the staff at the University of Alberta Hospital as a clinician and researcher. He was instrumental in the development of and co-directed both the Bebensee Schizophrenia Research Unit and the Edmonton Early Psychosis Intervention Clinic.
In 2008 Dr. Tibbo was named the first Dr. Paul Janssen Chair in Psychotic Disorders, an endowed research chair, at Dalhousie University in Halifax NS. He is a Professor in the Department of Psychiatry with a cross-appointment in Psychology and Neuroscience at Dalhousie University. He is Director of Research for the Department of Psychiatry at Dalhousie and Clinical Director of the provincial Early Psychosis Intervention Nova Scotia (EPINS) program for Nova Scotia Health. Dr Tibbo is President of the Canadian Consortium for Early Intervention in Psychosis (CCEIP), helping to advance early intervention care at the national level.
Dr. Tibbo’s publications are primarily in the area of schizophrenia with his current foci of study including individuals at the early phase of, and at risk for, a psychotic illness. Dr. Tibbo’s areas of research include application of in vivo brain neuroimaging techniques to study psychosis as well as research interests in co-morbidities in schizophrenia (primarily substance misuse and psychosis), pathways to care/service delivery, education, and non-pharmacological treatment options. He is funded by local and national peer reviewed funding agencies and well published in leading journals. Dr Tibbo was a recipient of the Canadian Alliance on Mental Illness and Mental Health’s Champion of Mental Health Research award in 2017 and the 2018 Royal College of Physicians and Surgeons of Canada Prix d’Excellence - Specialist of the Year (region 5).
Dr. Atul Khullar is a psychiatrist and sleep specialist who focuses on the integrative management of obesity, sleep, mood/anxiety and attention deficit disorders in age groups from adolescence onwards. Recently, he has gained expertise in the selective use of ketamine for resistant mood disorders.
He completed his medical school and residency at the University of Alberta, and a sleep and mood/anxiety disorders fellowship at the University of Toronto. He has additional pediatric sleep medicine training from the University of Pennsylvania.
Dr. Khullar is board-certified in Psychiatry and Sleep Medicine in both Canada and the United States. He is also a fellow of the American Academy of Sleep Medicine, Diplomate of the American Board of Obesity Medicine, and a Clinical Associate Professor at the University of Alberta.
Actively involved in research and education, Dr. Khullar has given more than 600 invited presentations to public and professional audiences worldwide. He has published a number of articles and chapters as well as chaired more than 20 national CME programs in his specialized areas.
Currently, he is the medical director of the Northern Alberta Sleep Clinic in Edmonton. Dr. Khullar is also a senior consultant for the Grey Nuns Hospital, the Edmonton Oilers, the Newly Institute and MedSleep, a Canada-wide network of community sleep clinics. He has also worked with the Canadian Winter Olympic team in the past.
Professor of Neurology, Department of Clinical Neurological Sciences
Western University, London, Ontario
Received MD from Western University, where I also did training in Internal Medicine and Neurology, receiving my fellowship in Neurology from the Royal College of Physicians and Surgeons of Canada.
I did a Medical Research Council of Canada sponsored research fellowship with Professor Joseph Martin at Harvard Medical School and the Massachusetts General Hospital in Boston and then returned to Western University in London Ontario.
Professor of Neurology in the Department of Clinical Neurological Sciences.
After doing General Neurology with a special interest in Neuroendocrinology for 39 years, I now limit my practice to headache Neurology.
MBBS, FRCPC
Director, UBC Headache Clinic
Associate Clinical Professor, Neurology
University of British Columbia
Dr. Spacey is a Neurologist and Clinical Associate Professor in the Division of Neurology at UBC. She completed a residency in Neurology at UBC and a fellowship in Neurogenetics at Queen Square, London England. She is Director of the UBC Headache Clinic and UBC Neurogenetics Clinic. She is past president of the Canadian Headache Society and Director of the UBC Clinician Investigator Program. She lectures nationally and internationally. Her research interest and publications are in the field of calcium channels and the pathogenesis and molecular genetics of migraine.
BSc MSc MD FRCPC, Pain Psychiatrist
Clinical Assistant Professor, University of British Columbia
Director, UBC Pain Medicine Residency Program
Dr. Michael Butterfield is a Clinical Assistant Professor at UBC with appointments in the Departments of Psychiatry and Anesthesiology, Pharmacology & Therapeutics. He has a keen interest in medical education and has been the Director of the UBC Pain Medicine Residency Program for 5 years. He practices clinically at various tertiary pain clinics and the UBC Headache Clinic. He is a member of several national committees in the areas of pain medicine and psychiatry and was recently awarded the Early Career Achievement in Psychiatry Award by the Canadian Psychiatric Association.
Message